Total Payments
$5,281
2024 Payments
$1,128
Companies
28
Transactions
195
Medicare Patients
5,602
Medicare Billing
$515,525
Payment Breakdown by Category
Food & Beverage$5,267 (99.7%)
Education$13.94 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,267 | 193 | 99.7% |
| Education | $13.94 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $1,079 | 38 | $0 (2024) |
| PFIZER INC. | $626.53 | 25 | $0 (2024) |
| Amgen Inc. | $558.19 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $497.92 | 12 | $0 (2023) |
| Abbott Laboratories | $493.91 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $391.45 | 17 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $357.46 | 15 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $229.60 | 4 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $165.40 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $141.12 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,128 | 35 | Amgen Inc. ($277.09) |
| 2023 | $826.77 | 20 | Abbott Laboratories ($346.55) |
| 2022 | $55.27 | 3 | Janssen Pharmaceuticals, Inc ($36.12) |
| 2021 | $273.67 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($135.75) |
| 2020 | $178.70 | 7 | Janssen Pharmaceuticals, Inc ($112.18) |
| 2019 | $818.56 | 28 | E.R. Squibb & Sons, L.L.C. ($212.04) |
| 2018 | $932.79 | 27 | PFIZER INC. ($321.14) |
| 2017 | $1,067 | 65 | E.R. Squibb & Sons, L.L.C. ($246.81) |
All Payment Transactions
195 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $134.52 | General |
| Category: Cardiology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: Cardiology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/26/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $38.33 | General |
| Category: Cardiology | ||||||
| 09/25/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $7.17 | General |
| Category: Cardiology | ||||||
| 09/17/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: Not Applicable | ||||||
| 09/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/20/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Cardiology | ||||||
| 07/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Cardiology | ||||||
| 07/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/20/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $80.87 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/20/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $27.05 | General |
| Category: Cardiology | ||||||
| 06/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Obesity | ||||||
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.27 | General |
| 05/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: DIABETES | ||||||
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.77 | General |
| 04/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: Cardiology | ||||||
| 04/10/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $18.57 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,375 | 2,546 | $527,514 | $142,080 |
| 2022 | 20 | 1,397 | 2,291 | $471,391 | $128,173 |
| 2021 | 20 | 1,428 | 2,626 | $494,656 | $133,955 |
| 2020 | 22 | 1,402 | 2,532 | $385,032 | $111,317 |
Total Patients
5,602
Total Services
9,995
Medicare Billing
$515,525
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 327 | 579 | $177,395 | $56,284 | 31.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 113 | 115 | $84,315 | $17,403 | 20.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 29 | 29 | $60,490 | $10,853 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 128 | 161 | $34,785 | $10,164 | 29.2% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 27 | 54 | $11,340 | $9,006 | 79.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 81 | $20,385 | $7,855 | 38.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 399 | 575 | $40,955 | $6,357 | 15.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 26 | 104 | $9,880 | $4,786 | 48.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 42 | 43 | $13,485 | $4,543 | 33.7% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 29 | 338 | $13,910 | $2,913 | 20.9% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 15 | 15 | $17,490 | $2,669 | 15.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 36 | 37 | $12,755 | $1,974 | 15.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 28 | 78 | $8,290 | $1,711 | 20.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 25 | $4,250 | $1,612 | 37.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 24 | 24 | $6,249 | $1,333 | 21.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 16 | 16 | $4,580 | $935.73 | 20.4% |
| 85610 | Blood test, clotting time | Office | 2023 | 21 | 219 | $3,535 | $912.02 | 25.8% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 20 | 20 | $1,635 | $325.17 | 19.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 14 | 17 | $945.00 | $293.25 | 31.0% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 15 | 16 | $845.00 | $149.28 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 286 | 422 | $129,300 | $44,466 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 248 | 315 | $66,545 | $18,813 | 28.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 81 | 85 | $64,135 | $13,481 | 21.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 23 | 23 | $43,705 | $9,237 | 21.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 45 | 78 | $20,425 | $6,588 | 32.3% |
About Dr. Jon Scheiber, M.D
Dr. Jon Scheiber, M.D is a Cardiovascular Disease healthcare provider based in Westerly, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417963737.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jon Scheiber, M.D has received a total of $5,281 in payments from pharmaceutical and medical device companies, with $1,128 received in 2024. These payments were reported across 195 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($5,267).
As a Medicare-enrolled provider, Scheiber has provided services to 5,602 Medicare beneficiaries, totaling 9,995 services with total Medicare billing of $515,525. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Westerly, RI
- Active Since 07/31/2006
- Last Updated 08/06/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1417963737
Products in Payments
- XARELTO (Drug) $1,079
- ELIQUIS (Drug) $820.88
- Repatha (Biological) $418.45
- ENTRESTO (Drug) $355.22
- CARDIOMEMS (Device) $346.55
- CHANTIX (Drug) $269.24
- JARDIANCE (Drug) $186.28
- PRADAXA (Drug) $171.18
- LifeVest (Device) $165.40
- CardioMEMS HF System (Device) $147.36
- Corlanor (Drug) $139.74
- UPTRAVI (Drug) $134.52
- Arcalyst (Drug) $113.39
- OPSUMIT (Drug) $95.08
- PRALUENT (Drug) $62.17
- ONPATTRO (Drug) $61.00
- PRALUENT ALIROCUMAB INJECTION (Biological) $55.53
- BRILINTA (Drug) $41.51
- PRALUENT (Biological) $41.12
- Veltassa (Drug) $39.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.